HBHelgi Birgisson

Helgi Birgisson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helgi Birgisson has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recruitment Strategies, Response Rates, and Non-Response Patterns in a Nationwide Registry-Based PRO Survey of Cancer Survivors and the General Population: The SURV-ICE Cohort

    by Kristjana Sigurðardóttir, Nanna Friðriksdóttir, Nanna Margrét Kristinsdóttir, Lára Kristjánsdóttir, Hjalti Gunnlaugur Skúlason, Álfheiður Haraldsdóttir, Sigríður Ása Alfonsdóttir, Anna Kristín B. Jóhannesdóttir, Helgi Birgisson, Helga Tryggvadóttir, et al.

    Background: Population-based studies using patient-reported outcomes provide important insights into health-related quality of life (HRQoL) and the long-term impact of cancer and its treatment. Declining response rates and potential non-response bias have presented methodological challenges, particularly in registry-based surveys including both cancer survivors and population controls. The SURV-ICE study was established to assess HRQoL and health literacy among cancer survivors in Iceland while evaluating recruitment processes and participation patterns in a nationwide mixed-mode survey. Methods: SURV-ICE is a nationwide, population-based cross-sectional survey conducted in Iceland in 2025. Adults diagnosed with invasive cancer between 2014 and 2024 were identified through the Icelandic Cancer Registry and invited alongside an age- and gender-matched control group sampled from national registers. Participants completed validated EORTC instruments. Recruitment used a mixed-mode strategy including postal invitations, web-based and paper questionnaires, electronic reminders via the national health portal, and targeted telephone follow-up. Results: Among 10,005 cancer survivors 5489 (54.9%) responded to the questionnaires and among 5663 controls 2297 (40.6%) responded to the questionnaires. In both groups participation peaked among individuals aged 60–79 years and was lowest among the youngest and oldest groups. Cancer survivors had higher odds of participation than controls (OR 1.84; 95% CI 1.72–1.97). Most responses followed the initial postal invitation and first electronic reminder. Data completeness was high (≥80% item completion in 95.7% of instruments). Conclusions: Nationwide registry-based recruitment for large-scale PRO research is feasible in Iceland and can achieve competitive response rates without incentives. SURV-ICE provides an infrastructure for future research on cancer survivorship, HRQoL, and health literacy.

  • Open Access

    Trends in lung cancer survival in the Nordic countries 1990–2016: The NORDCAN survival studies

    by Frida E. Lundberg, Simon Ekman, Anna L.V. Johansson, Gerda Engholm, Helgi Birgisson, Elínborg J. Ólafsdóttir, Lina Steinrud Mørch, Tom Børge Johannesen, Therese M.-L. Andersson, David Pettersson, et al.


  • Screening for cancer of the colon and rectum A review on incidence, mortality, cost and benefit

    by Helgi Birgisson, Elínborg J. Ólafsdóttir, Anna Sverrisdóttir, Sigurður Einarsson, Agnes Smáradóttir, Laufey Tryggvadóttir, The Medical Clinic Center Of Medical Gastroenterology

    Key words: Colorectal cancer, Screening, Incidence, Mortality, Cost-effectiveness In this article the incidence and mortality for cancer of the colon and rectum in Iceland is discussed. The two most common screening methods, faecal immunochemical test (FIT) and colonoscopy are compared and an estimate of cost and benefits for the Icelandic society will be made. The incidence of cancer of the colon and rectum has been increasing in Iceland in last decades but mortality has decreased and survival improved. However, more individuals die from cancer of the colon and rectum than from both breast- and cervical cancer added together. It is likely that screening for cancer of the colon and rectum, could prevent at least 6 of the 28 deaths related to those cancers, occurring yearly in Iceland in screening age, given a screening ages of 50-74 years. The extra cost for the Icelandic community due to the implementation of screening for cancer of the colon and rectum will be acceptable due to the lower cost of simpler treatments, lower cancer incidence and reduced mortality.